Clinical trial
An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
NCT03085810 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 24, 2017
- Completion date
- April 27, 2023
- Enrollment
- 1,225 (actual)
- Sites
- 193
Conditions
As the registry lists them; a condition with its own page is linked.